Critical appraisal of pazopanib as treatment for patients with advanced metastatic renal cell carcinoma

References

• JemalASiegelRXuJWardECancer statistics, 2010CA Cancer J Clin.201060527730020610543
   PubMed Web of Science ®Google Scholar
• FerlayJShinHRBrayFFormanDMathersCParkinDMInternational Agency for Research on CancerGLOBOCAN 2008Cancer incidence and mortality worldwide: CancerBase102008 Available from: http://globocan.iarc.frAccessed June 21, 2011
   Google Scholar
• TsivianMMoreiraDMCasoJRMouravievVPolascikTJCigarette smoking is associated with advanced renal cell carcinomaJ Clin Oncol.201129152027203121502558
   PubMed Web of Science ®Google Scholar
• YoungACCravenRACohenDAnalysis of VHL gene alterations and their relationship to clinical parameters in sporadic conventional renal cell carcinomaClin Cancer Res.200915247582759219996202
   PubMed Web of Science ®Google Scholar
• VarelaITarpeyPRaineKExome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinomaNature.2011469733153954221248752
   PubMed Web of Science ®Google Scholar
• GeorgeDJKaelinWGJrThe von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancerN Engl J Med.2003349541942112890838
   PubMed Web of Science ®Google Scholar
• ButmanJALinehanWMLonserRRNeurologic manifestations of von Hippel-Lindau diseaseJAMA.2008300111334134218799446
   PubMed Web of Science ®Google Scholar
• LatifFToryKGnarraJIdentification of the von Hippel–Lindau disease tumor suppressor geneScience.19932605112131713208493574
   PubMed Web of Science ®Google Scholar
• KaelinWGJrThe von Hippel-Lindau tumor suppressor protein and clear cell renal carcinomaClin Cancer Res.2007132 Pt 2680s684s17255293
   PubMed Web of Science ®Google Scholar
• MotzerRJBacikJMurphyBARussoPMazumdarMInterferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinomaJ Clin Oncol.200220128929611773181
   PubMed Web of Science ®Google Scholar
• MekhailTMAbou-JawdeRMBoumerhiGValidation and extension of the memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinomaJ Clin Oncol.200523483284115681528
   PubMed Web of Science ®Google Scholar
• HengDYXieWReganMMPrognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter studyJ Clin Oncol.200927345794579919826129
   PubMed Web of Science ®Google Scholar
• RiniBICampbellSCEscudierBRenal cell carcinomaLancet.200937396691119113219269025
   PubMed Web of Science ®Google Scholar
• AtkinsMBReganMMcDermottDUpdate on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinomaClin Cancer Res.20041018 Pt 26342S6346S15448028
   PubMed Web of Science ®Google Scholar
• MotzerRJHutsonTETomczakPSunitinib versus interferon alfa in metastatic renal-cell carcinomaN Engl J Med.2007356211512417215529
   PubMed Web of Science ®Google Scholar
• EscudierBEisenTStadlerWMSorafenib in advanced clear-cell renal-cell carcinomaN Engl J Med.2007356212513417215530
   PubMed Web of Science ®Google Scholar
• SternbergCNDavisIDMardiakJPazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trialJ Clin Oncol.20102861061106820100962
   PubMed Web of Science ®Google Scholar
• HudesGCarducciMTomczakPTemsirolimus, interferon alfa, or both for advanced renal-cell carcinomaN Engl J Med.2007356222271228117538086
   PubMed Web of Science ®Google Scholar
• MotzerRJEscudierBOudardSEfficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialLancet.2008372963744945618653228
   PubMed Web of Science ®Google Scholar
• EscudierBPluzanskaAKoralewskiPBevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialLancet.200737096052103211118156031
   PubMed Web of Science ®Google Scholar
• LiuDQChenTKMcGuireMAKordASAnalytical control of genotoxic impurities in the pazopanib hydrochloride manufacturing processJ Pharm Biomed Anal.200950214415019427156
   PubMed Web of Science ®Google Scholar
• HarrisPACheungMHunterRN3rdDiscovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR-2 kinase inhibitorsJ Med Chem.20054851610161915743202
   PubMed Web of Science ®Google Scholar
• HarrisPABoloorACheungMDiscovery of 5-[[4-[(2,3- dimethyl-2H-indazol-6-yl)methylamino]-2 pyrimidinyl]amino] 2 methylbenzenesulfonamide (pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitorJ Med Chem.200851154632464018620382
   PubMed Web of Science ®Google Scholar
• KumarRKnickVBRudolphSKPharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activityMol Cancer Ther.2007672012202117620431
   PubMed Web of Science ®Google Scholar
• HurwitzHIDowlatiASainiSPhase I trial of pazopanib (GW786034), an oral multikinaseangiogenesis inhibitor, in patients with advanced cancer: results of safety, pharmacokinetics, and clinical activityClin Cancer Res.200915124220422719509175
   PubMed Web of Science ®Google Scholar
• Food and Drug AdministrationVotrient^TM. Full prescribing information102009 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022465lbl.pdfAccessed July 23, 2011
   Google Scholar
• RatainMJEisenTStadlerWMPhase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinomaJ Clin Oncol.200624162505251216636341
   PubMed Web of Science ®Google Scholar
• HutsonTEDavisIDMachielsJHEfficacy and safety of pazopanib in patients with metastatic renal cell carcinomaJ Clin Oncol.201028347548020008644
   PubMed Web of Science ®Google Scholar
• SternbergCNHawkinsRESzczylikCRandomized, double- blind phase III study of pazopanib in patients with advanced/metastatic renal cell carcinoma (MRCC): final overall survival (OS) resultsAnn Oncol201021Suppl 8 abstract LBA22
   Google Scholar
• SternbergCNHawkinsRESzczylikCA randomized, double-blind phase III study (VEG105192) of pazopanib (paz) versus placebo (pbo) in patients with advanced/metastatic renal cell carcinoma (mRCC): updated safety resultsJ Clin Oncol201129Suppl 7 abstract 313
   Web of Science ®Google Scholar
• RiniBIHalabiSRosenbergJEPhase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206J Clin Oncol.201028132137214320368558
   PubMed Web of Science ®Google Scholar
• EscudierBSzczylikCHutsonTERandomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinomaJ Clin Oncol.20092781280128719171708
   PubMed Web of Science ®Google Scholar
• RiniBISzczylikCTannirNMAMG 386 in combination with sorafenib in patients (pts) with metastatic renal cell cancer (mRCC): a randomized, double-blind, placebo-controlled, phase II studyJ Clin Oncol201129Suppl 7 abstract 309
   Web of Science ®Google Scholar
• MotzerRJHutsonTETomczakPOverall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinomaJ Clin Oncol.200927223584359019487381
   PubMed Web of Science ®Google Scholar
• EscudierBBellmuntJNegrierSPhase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survivalJ Clin Oncol.201028132144215020368553
   PubMed Web of Science ®Google Scholar
• RiniBIHalabiSRosenbergJEBevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206J Clin Oncol.200826335422542818936475
   PubMed Web of Science ®Google Scholar
• McCannLAmitOPanditeLAmadoRGAn indirect comparison analysis of pazopanib versus other agents in metastatic renal cell carcinoma (mRCC)J Clin Oncol201028Suppl abstract e15128
   Google Scholar
• EscudierBEisenTStadlerWMSorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trialJ Clin Oncol.200927203312331819451442
   PubMed Web of Science ®Google Scholar
• HengDYXieWBjarnasonGAProgression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapyCancer.2011117122637264221656741
   PubMed Web of Science ®Google Scholar
• ReevesJASpigelDRDanielDBFriedmanEKBurrisHAHainsworthJDPazopanib in patients with metastatic renal cell carcinoma previously treated with sunitinib or bevacizumab: a Sarah Cannon Research Institute phase II trialJ Clin Oncol201129Suppl abstract 4659
   PubMedGoogle Scholar
• MatranaMRAtkinsonBJCornPGJonaschETannirNMMetastatic renal cell carcinoma treated with pazopanib after progression on other targeted agents: a single-institution experienceJ Clin Oncol201129Suppl 7 abstract 351
   Web of Science ®Google Scholar
• ClinicalTrials.govAn open-label pharmacodynamic study of bevacivumab and pazopanib in renal cell carcinoma Oct 82009 Available from: http://clinicaltrials.gov/ct2/show/NCT00992121Accessed June 22, 2011
   Google Scholar
• ClinicalTrials.govPazopanib and everolimus in patients with advanced solid tumors and previously treated kidney cancer Aug 172010 Available from: http://clinicaltrials.gov/ct2/show/NCT01184326Accessed June 22, 2011
   Google Scholar
• SemradTJEddingsCDutiaMPChristensenSLauDLaraPPhase I study of temsirolimus (Tem) and pazopanib (Paz) in solid tumors with emphasis on renal cell carcinoma (RCC)J Clin Oncol201129Suppl abstract e15113
   Google Scholar
• XuCBingNXBallHAPazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genesJ Clin Oncol.201129182557256421576632
   PubMed Web of Science ®Google Scholar
• XuCBallHABingNAssociation of genetic markers in angiogenesis- or exposure-related genes with overall survival in pazopanib (P) treated patients (Pts) with advanced renal cell carcinomaJ Clin Oncol201129Suppl 7 abstract 303
   Web of Science ®Google Scholar
• HoukBEBelloCLPolandBRosenLSDemetriGDMotzerRJRelationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysisCancer Chemother Pharmacol.201066235737119967539
   PubMed Web of Science ®Google Scholar
• SuttleBBallHAMolimardMRelationship between exposure to pazopanib (P) and efficacy in patients (pts) with advanced renal cell carcinoma (mRCC)J Clin Oncol201028Suppl abstract 3048
   Google Scholar
• ClinicalTrials.govPazopanib versus sunitinib in the treatment of locally advanced and/or metastatic renal cell carcinoma (COMPARZ) July 222008 Available from: http://clinicaltrials.gov/ct2/show/NCT00720941Accessed June 22, 2011
   Google Scholar
• ClinicalTrials.govPatient preference study of pazopanib versus sunitinib in advanced or metastatic kidney cancer (PISCES) February 42010 Available from: http://clinicaltrials.gov/ct2/show/NCT01064310Accessed June 22, 2011
   Google Scholar
• KapadiaSHapaniSWuSRisk of high-grade liver toxicity with pazopanib in patients with cancer: a meta-analysisJ Clin Oncol201129Suppl abstract 4595
   Google Scholar
• PickardACellaDDuhMSHealth-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomized phase III trialJ Clin Oncol201129Suppl abstract 9096
   Google Scholar
• CoppinCPorzsoltFAwaAKumpfJColdmanAWiltTImmunotherapy for advanced renal cell cancerCochrane Database Syst Rev20051CD00142515674877
   PubMed Web of Science ®Google Scholar